⚠️ IMPORTANT NOTICE FOR INVESTORS
Investment opportunities with AfriPharma Health Systems Ltd are private placements available exclusively to accredited or qualified investors.
This website does not constitute an offer to sell securities or a solicitation of investment. All investment discussions require:
- Execution of Non-Disclosure Agreement (NDA)
- Verification of accredited investor status
- Access to formal investment documentation
- Due diligence review
For investor inquiries: invest@afripharma-health.com
See our full Disclaimer for important information about investment risks and forward-looking statements.
Investment Opportunity
Building pharmaceutical sovereignty in Africa with measurable impact and financial returns
Project Overview
AfriPharma Health Systems is raising $12 million to establish Mozambique's first WHO Prequalification-aligned pharmaceutical manufacturing facility for sterile injectables.
Location
Nacala Special Economic Zone, Mozambique
Products
7 WHO Essential Medicines (sterile injectables)
Capacity
21.6 million vials annually
Market
$3.2B SADC pharmaceutical market, 380M people
Timeline
Construction 2026, Commercial launch 2027
Impact
150+ jobs, $50M+ import substitution by Year 5
Capital Structure
Total Project Cost: $12 million
- Equity Raise: $6 million
- Senior Debt: $4 million (DFI partners)
- Grants/Co-funding: $2 million
Investment Highlights
- First-mover advantage: No WHO PQ-aligned facilities in Mozambique
- Strategic location: Nacala port provides efficient access to SADC markets
- Strong unit economics: Local production with 20-30% cost advantage
- Government support: SEZ incentives, regulatory commitment, industrialization alignment
- Impact + Returns: Measurable social impact with commercial returns
- De-risked pathway: Proven products, established market demand, WHO standards
Use of Funds
- Facility Construction: 45%
- Manufacturing Equipment: 35%
- Working Capital: 10%
- Regulatory/WHO PQ: 7%
- Contingency: 3%
Target Investor Types
We welcome inquiries from:
- Development Finance Institutions (DFIs)
- Impact investors with healthcare/Africa focus
- Healthcare-focused private equity funds
- Strategic pharmaceutical partners
- Family offices with impact mandates
- Institutional investors focused on emerging markets
Leadership Team
Brighton Muresherwa
Strategic Lead
Brighton leads strategic partnerships and stakeholder engagement across the SADC region, managing government relations, investor communications, and market entry strategy for AfriPharma's pharmaceutical manufacturing initiative.
For inquiries regarding the full executive team and governance structure, accredited investors may request access to the private Investor Portal.
Next Steps for Investors
- Submit Inquiry: Email invest@afripharma-health.com
- Execute NDA: Sign Non-Disclosure Agreement
- Access Investor Portal: Receive credentials for detailed materials
- Due Diligence Review: Access financial models, legal docs, site visit arrangements
- Investment Committee: Present to your investment committee
- Term Sheet: Negotiate investment terms
- Legal Documentation: Complete subscription agreements
Ready to Learn More?
Financial projections, return estimates, and detailed business plans are available only to qualified investors through our secure Investor Portal.
Contact: invest@afripharma-health.com
Important: Information on this public website is illustrative only and does not constitute investment advice or an offer to sell securities. All investment opportunities are subject to applicable securities laws and available only to accredited investors who have executed appropriate legal documentation.